• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
ProAxsis receives further backing from Invest Northern Ireland under EU investment
Share
News

ProAxsis receives further backing from Invest Northern Ireland under EU investment

June 1, 2018
-
Posted by David Ribeiro

ProAxsis Limited has received an Invest NI Grant for Research and Development, supporting the company to develop new products using its innovative ProteaseTag® technology. The grant is part financed under the European Union’s Investment for Growth and Jobs Programme for Northern Ireland.  The project, entitled “The development of ProteaseTags® for deubiquitinases (DUBs): innovative tools for biomarker identification and drug discovery in oncology”, will be implemented over the next 12 months and aims to allow the design and synthesis of peptide-based inhibitors for the DUBs family, followed by an assessment of their incorporation in to prototype activity-based immunoassay formats.

Dr David Ribeiro, CEO of ProAxsis, commented: “Deubiquitinases are known to play important roles in various diseases including different forms of cancer and neurodegeneration, and therefore represent potential therapeutic targets of high interest to the pharmaceutical industry. We’re excited to explore the expansion of our novel ProteaseTag® technology to measure this family of cysteine proteases, and are extremely grateful to Invest NI, who continue to support our ongoing efforts to establish ProAxsis as a global leader in the design, development and commercialisation of highly specific assays for the measurement of active protease biomarkers of disease.”

ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.

To find out how ProAxsis can support the measurement of active protease biomarkers of disease, or for any further queries, please contact info@proaxsis.com

June 1, 2018

Related News

Other posts that you should not miss.
News

ProAxsis shortlisted for Small Business of the Year Award

November 18, 2019
-
Posted by David Ribeiro

ProAxsis is delighted to have been shortlisted for a Business Eye First Trust Award for the second …

Read More
November 18, 2019
Posted by David Ribeiro
News

New opportunity for Early Stage Researcher at Queen’s University Belfast

March 6, 2018
-
Posted by David Ribeiro

ProAxsis is proud to be collaborating with Dr. Gunnar Schroeder and Prof. Cliff Taggart from the School …

Read More
March 6, 2018
Posted by David Ribeiro
Conferences, News

ProAxsis to present at 2016 American Thoracic Society Conference

May 16, 2016
-
Posted by Webmaster

ProAxsis will this week be presenting further data on its ProteaseTag® Active Neutrophil Elastase (NE) Immunoassay, at the American …

Read More
May 16, 2016
Posted by Webmaster
← PREVIOUS POST
ProAxsis wins Innovative Business of the Year Award
NEXT POST →
ProAxsis Presenting New Data on NEATstik and New High Sensitivity Neutrophil Elastase Immunoassay at ATS 2018
Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis Limited appoints first distributor for DACH region
    December 14, 2020

    ProAxsis Limited (www.proaxsis.com), the Belfast-based diagnostics company specialising in the measurement of active …

  • ProAxsis Limited supported by Innovate UK to accelerate work on inflammatory biomarkers associated with COVID-19
    December 10, 2020

    ProAxsis (www.proaxsis.com), the Belfast-based respiratory diagnostics company, today announces that it has been …

  • ProAxsis Limited recognised as Gold Level Innovator by Innovate NI
    December 2, 2020

    ProAxsis (www.proaxsis.com), the Belfast-based protease diagnostics company, is delighted to announce that it …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • February 21, 2021
    ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
  • December 14, 2020
    ProAxsis Limited appoints first distributor for DACH region
  • December 10, 2020
    ProAxsis Limited supported by Innovate UK to accelerate work on inflammatory biomarkers associated with COVID-19
LATEST TWEETS
Twitter
ProAxsis
Follow Me
ProAxsis is delighted to have received this support from Innovate UK - https://t.co/toTxOz9KK6
82 days ago
- ProAxsis
RT @GRobinsonDUP: I’m delighted that @ProAxsis based in East Belfast have been successful in their application for an Innovate UK Grant, wh…
82 days ago
- ProAxsis
We are delighted to announce that as of today, we have appointed an exclusive distributor for our portfolio of prod… https://t.co/rmCmIugsLa
103 days ago
- ProAxsis
Due to our continued expansion, we wish to recruit an Administration Officer. This post can be full-time or part-ti… https://t.co/k3wKwVfOKy
122 days ago
- ProAxsis
Copyright © 2016-2021 - ProAxsis - All rights reserved. 
ProAxsis receives further backing from Invest Northern Ireland under EU investment | ProAxsis